Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(23)02463-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.
Front Immunol
December 2024
Institute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Background: Immune checkpoint inhibitors (ICIs) treatment have shown high efficacy for about 15 cancer types. However, this therapy is only effective in 20-30% of cancer patients. Thus, the precise biomarkers of ICI response are an urgent need.
View Article and Find Full Text PDFIn silico neoantigen screening and HLA multimer-based validation identify immunogenic neopeptide in multifocal lung adenocarcinoma.
Front Immunol
December 2024
Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background: Mutations commonly occur in cancer cells, arising neoantigen as potential targets for personalized immunotherapy of lung adenocarcinoma (LUAD). However, the substantial heterogeneity observed among individuals and distinct foci within the same patient presents significant challenges in formulating immunotherapy strategies. The aim of the work is to characterize the mutation pattern and identify neopeptides across different patients and diverse foci within the same patients with LUAD.
View Article and Find Full Text PDFAddition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.
Signal Transduct Target Ther
December 2024
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, PR China.
This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β, in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxaliplatin) as a first-line treatment for unresectable metastatic colorectal cancer (mCRC). In this phase 2 study, a total of 62 patients with untreated, histologically confirmed colorectal adenocarcinoma and no prior systemic therapy for metastatic disease were enrolled. Patients received SHR-1701 (30 mg/kg), bevacizumab (7.
View Article and Find Full Text PDFIdentification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer.
J Cancer Res Clin Oncol
December 2024
Department of Pathology, Medical College of Georgia at Augusta University, 1120 15th Street, Augusta, GA, 30912, BF-207, USA.
Background: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Despite advances in diagnosis and treatment, including surgery, chemotherapy, and immunotherapy, accurate clinical markers are still lacking. The development of prognostic and predictive indicators, particularly in the context of personalized medicine, could significantly improve CRC patient management.
View Article and Find Full Text PDFAdjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.
EBioMedicine
December 2024
Mater Research Institute, University of Queensland, Brisbane, QLD, Australia; Princess Alexandra Hospital, Brisbane, QLD, Australia. Electronic address:
Article Synopsis
- The study followed patients with early-stage follicular lymphoma (ESFL) who were treated with involved field radiotherapy (IFRT) alone or combined with chemotherapy (cyclophosphamide/vincristine/prednisolone) and later added rituximab to the treatment, analyzing its effects over an 11.3-year period.* -
- Results showed that those receiving IFRT plus rituximab (IFRT + R-CVP) had significantly better progression-free survival rates (62% vs. 43%) compared to IFRT alone, even though overall survival rates didn’t differ significantly.* -
- Additionally, higher expression of the CD8A gene in biopsy samples was associated with improved outcomes, suggesting that immune
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!